[
    {
        "id": "controlled_release_oral_forms",
        "title": "Pharmaceutical Technology of Modified Release Dosage Forms",
        "content": "Controlled release solid oral formulations represent significant pharmaceutical advances enabling optimized pharmacokinetic profiles and enhanced therapeutic outcomes through various technological approaches. Hydrophilic matrix systems utilize gel-forming polymers including hydroxypropylmethylcellulose or sodium alginate to create a viscous diffusion barrier upon hydration, with drug release regulated through manipulation of polymer type, concentration, and matrix geometry. These systems demonstrate reliable zero-order release kinetics for moderately water-soluble compounds through balanced diffusion and erosion mechanisms. Film-coated tablets incorporating insoluble polymeric membranes (e.g., ethylcellulose, polymethacrylates) provide alternative controlled-release mechanisms, with drug diffusion occurring through the intact coating following aqueous penetration. Coating thickness, polymer selection, and incorporation of pore-forming agents enable precise release rate customization for diverse therapeutic requirements. Complex multi-compartment designs including double-core formulations incorporate separate compartments with distinct release characteristics, enabling pulsatile or sequential drug delivery impossible with conventional monolithic systems. Ion-exchange resin complexation represents another effective controlled-release approach, with drug molecules ionically bound to resin particles and subsequently released through ion exchange with the gastrointestinal environment at rates determined by resin properties, drug characteristics, and local ionic conditions. Lipophilic matrix systems employing waxes, fatty acids, or glycerides create hydrophobic diffusion barriers with drug release controlled through erosion and limited aqueous penetration of the matrix. These diverse technological approaches enable pharmaceutical scientists to design continuous drug release profiles specifically tailored to therapeutic requirements, patient needs, and physicochemical properties of active pharmaceutical ingredients, collectively advancing rational drug delivery beyond conventional immediate-release formulations.",
        "contents": "Pharmaceutical Technology of Modified Release Dosage Forms. Controlled release solid oral formulations represent significant pharmaceutical advances enabling optimized pharmacokinetic profiles and enhanced therapeutic outcomes through various technological approaches. Hydrophilic matrix systems utilize gel-forming polymers including hydroxypropylmethylcellulose or sodium alginate to create a viscous diffusion barrier upon hydration, with drug release regulated through manipulation of polymer type, concentration, and matrix geometry. These systems demonstrate reliable zero-order release kinetics for moderately water-soluble compounds through balanced diffusion and erosion mechanisms. Film-coated tablets incorporating insoluble polymeric membranes (e.g., ethylcellulose, polymethacrylates) provide alternative controlled-release mechanisms, with drug diffusion occurring through the intact coating following aqueous penetration. Coating thickness, polymer selection, and incorporation of pore-forming agents enable precise release rate customization for diverse therapeutic requirements. Complex multi-compartment designs including double-core formulations incorporate separate compartments with distinct release characteristics, enabling pulsatile or sequential drug delivery impossible with conventional monolithic systems. Ion-exchange resin complexation represents another effective controlled-release approach, with drug molecules ionically bound to resin particles and subsequently released through ion exchange with the gastrointestinal environment at rates determined by resin properties, drug characteristics, and local ionic conditions. Lipophilic matrix systems employing waxes, fatty acids, or glycerides create hydrophobic diffusion barriers with drug release controlled through erosion and limited aqueous penetration of the matrix. These diverse technological approaches enable pharmaceutical scientists to design continuous drug release profiles specifically tailored to therapeutic requirements, patient needs, and physicochemical properties of active pharmaceutical ingredients, collectively advancing rational drug delivery beyond conventional immediate-release formulations."
    },
    {
        "id": "paracetamol_poisoning",
        "title": "Management Approaches for Acetaminophen Toxicity",
        "content": "Paracetamol (acetaminophen) overdose represents a common and potentially life-threatening poisoning requiring evidence-based management approaches guided by pharmacokinetic and metabolic considerations. Initial interventions focus on reducing absorption, with substantial evidence supporting early activated charcoal administration when patients present within 1-2 hours post-ingestion. Multiple controlled studies document 50-70% reductions in paracetamol bioavailability following timely charcoal administration, significantly altering toxicity risk assessments. Gastrointestinal decontamination approaches include gastric lavage, which demonstrates particular utility when performed within 60 minutes of ingestion for substantial overdoses, representing an important intervention alongside activated charcoal in early presentations. The hepatotoxicity mechanism involves a complex metabolic pathway wherein a small percentage of paracetamol undergoes cytochrome P450-mediated (primarily CYP2E1) biotransformation generating the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and subsequently binds cellular proteins causing hepatocellular damage. Antidotal therapy with N-acetylcysteine works through multiple mechanisms including glutathione precursor provision and alternative metabolic pathway enhancement, with administration protocols varying between oral and intravenous routes. Importantly, concurrent administration of oral N-acetylcysteine with activated charcoal results in significant adsorption and reduced antidote bioavailability, necessitating dosage adjustments or separated administration when both interventions are indicated. Clinical progression typically follows a characteristic pattern, with hepatotoxicity markers including transaminase elevations developing 24-48 hours post-ingestion rather than presenting as early manifestations, contrasting with other toxic presentations where renal dysfunction may present earlier. These pharmacological and clinical characteristics inform evidence-based management approaches balancing gastrointestinal decontamination, antidotal therapy, and supportive care for optimal outcomes.",
        "contents": "Management Approaches for Acetaminophen Toxicity. Paracetamol (acetaminophen) overdose represents a common and potentially life-threatening poisoning requiring evidence-based management approaches guided by pharmacokinetic and metabolic considerations. Initial interventions focus on reducing absorption, with substantial evidence supporting early activated charcoal administration when patients present within 1-2 hours post-ingestion. Multiple controlled studies document 50-70% reductions in paracetamol bioavailability following timely charcoal administration, significantly altering toxicity risk assessments. Gastrointestinal decontamination approaches include gastric lavage, which demonstrates particular utility when performed within 60 minutes of ingestion for substantial overdoses, representing an important intervention alongside activated charcoal in early presentations. The hepatotoxicity mechanism involves a complex metabolic pathway wherein a small percentage of paracetamol undergoes cytochrome P450-mediated (primarily CYP2E1) biotransformation generating the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and subsequently binds cellular proteins causing hepatocellular damage. Antidotal therapy with N-acetylcysteine works through multiple mechanisms including glutathione precursor provision and alternative metabolic pathway enhancement, with administration protocols varying between oral and intravenous routes. Importantly, concurrent administration of oral N-acetylcysteine with activated charcoal results in significant adsorption and reduced antidote bioavailability, necessitating dosage adjustments or separated administration when both interventions are indicated. Clinical progression typically follows a characteristic pattern, with hepatotoxicity markers including transaminase elevations developing 24-48 hours post-ingestion rather than presenting as early manifestations, contrasting with other toxic presentations where renal dysfunction may present earlier. These pharmacological and clinical characteristics inform evidence-based management approaches balancing gastrointestinal decontamination, antidotal therapy, and supportive care for optimal outcomes."
    },
    {
        "id": "SelfCorpus 9",
        "title": "Growth promoting effects of IGF-1",
        "content": "The first demonstration that exogenous IGF-1 stimulates growth was the administration of purified hormone to hypophysectomised rats. After the biosynthesis of IGF-1 identical to the native hormone, trials of its use in humans were begun; first in adults and then in children. Our group was the first to introduce long term administration of biosynthetic IGF-1 to children with primary IGF-1 deficiency\u2014primary GH insensitivity or LS. The finding that daily IGF-1 administration raises serum alkaline phosphatase, which is an indicator of osteoblastic activity, and serum procollagen, in addition to IGFBP-3, led to long term treatment. Treatment of patients with LS was also initiated in other parts of the world. The difference between us and the other groups was that we used a once daily dose, whereas the others administered IGF-1 twice daily. Table 1 compares the linear growth response of children with LS treated by four different groups. It can be seen that before treatment the mean growth velocity was 3\u20134.7 cm/year and that this increased after IGF-1 treatment to 8.2\u20139.1 cm/year, followed by a lower velocity of 5.5\u20136.4 cm/year in the next two years. (In GH treatment the highest growth velocity registered is also in the first year of treatment.) Figure 5 illustrates the growth response to IGF-1 in eight children during the first years of treatment. Ranke and colleagues reported that two of their patients had reached the third centile (Tanner), as did the patient of Krzisnik and Battelino; however, most patients did not reach a normal final height. The reasons may be late initiation of treatment, irregular IGF-1 administration, underdosage, etc. Ranke et al conclude that long term treatment of patients with LS promoted growth and, if treatment is started at an early age, there is a considerable potential for achieving height normalisation. Because no patient in our group was treated since early infancy to final height we cannot confirm this opinion. When the growth response to GH treatment in infants with IGHD was compared with that of IGF-1 in infants with LS we found that the infants with IGHD responded faster and better than those with LS. However, the small number of patients and the differences in growth retardation between the two groups makes it difficult to reach a conclusion. Both hormones stimulated linear growth, but GH seemed more effective than IGF-1. One cause may be the greater growth deficit of the infants with LS than those with IGHD, an insufficient dose of IGF-1, or that there is a need for some GH to provide an adequate stem cell population of prechondrocytes to enable full expression of the growth promoting action of IGF-1, as postulated by Green and colleagues and Ohlson et al. All the above findings based on a few clinical studies with small groups of patients and a few experimental studies remain at present controversial. The crucial question is whether there are any, and if so, whether there are sufficient IGF-1 receptors in the \u201cprogenitor cartilage zone\u201d of the epiphyseal cartilage to respond to endocrine and exogenous IGF-1. Using the mandibular condyle of 2 day old ICR mice, Maor et al showed that these condyles, which resemble the epiphyseal plates of the long bones, contain IGF-1 and high affinity IGF-1 receptors also in the chondroprogenitor cell layers, which enables them to respond to IGF-1 in vitro. Sims et al, using mice with GH receptor KO, showed that IGF-1 administration stimulates the growth (width) of the tibial growth plate and that IGF-1 has a GH independent effect on the growth plate. These findings are similar to those found when treating hypophysectomised rats with IGF-1. In conclusion, IGF-1 is an important growth hormone, mediating the anabolic and linear growth promoting effect of pituitary GH protein. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.",
        "contents": "Growth promoting effects of IGF-1. The first demonstration that exogenous IGF-1 stimulates growth was the administration of purified hormone to hypophysectomised rats. After the biosynthesis of IGF-1 identical to the native hormone, trials of its use in humans were begun; first in adults and then in children. Our group was the first to introduce long term administration of biosynthetic IGF-1 to children with primary IGF-1 deficiency\u2014primary GH insensitivity or LS. The finding that daily IGF-1 administration raises serum alkaline phosphatase, which is an indicator of osteoblastic activity, and serum procollagen, in addition to IGFBP-3, led to long term treatment. Treatment of patients with LS was also initiated in other parts of the world. The difference between us and the other groups was that we used a once daily dose, whereas the others administered IGF-1 twice daily. Table 1 compares the linear growth response of children with LS treated by four different groups. It can be seen that before treatment the mean growth velocity was 3\u20134.7 cm/year and that this increased after IGF-1 treatment to 8.2\u20139.1 cm/year, followed by a lower velocity of 5.5\u20136.4 cm/year in the next two years. (In GH treatment the highest growth velocity registered is also in the first year of treatment.) Figure 5 illustrates the growth response to IGF-1 in eight children during the first years of treatment. Ranke and colleagues reported that two of their patients had reached the third centile (Tanner), as did the patient of Krzisnik and Battelino; however, most patients did not reach a normal final height. The reasons may be late initiation of treatment, irregular IGF-1 administration, underdosage, etc. Ranke et al conclude that long term treatment of patients with LS promoted growth and, if treatment is started at an early age, there is a considerable potential for achieving height normalisation. Because no patient in our group was treated since early infancy to final height we cannot confirm this opinion. When the growth response to GH treatment in infants with IGHD was compared with that of IGF-1 in infants with LS we found that the infants with IGHD responded faster and better than those with LS. However, the small number of patients and the differences in growth retardation between the two groups makes it difficult to reach a conclusion. Both hormones stimulated linear growth, but GH seemed more effective than IGF-1. One cause may be the greater growth deficit of the infants with LS than those with IGHD, an insufficient dose of IGF-1, or that there is a need for some GH to provide an adequate stem cell population of prechondrocytes to enable full expression of the growth promoting action of IGF-1, as postulated by Green and colleagues and Ohlson et al. All the above findings based on a few clinical studies with small groups of patients and a few experimental studies remain at present controversial. The crucial question is whether there are any, and if so, whether there are sufficient IGF-1 receptors in the \u201cprogenitor cartilage zone\u201d of the epiphyseal cartilage to respond to endocrine and exogenous IGF-1. Using the mandibular condyle of 2 day old ICR mice, Maor et al showed that these condyles, which resemble the epiphyseal plates of the long bones, contain IGF-1 and high affinity IGF-1 receptors also in the chondroprogenitor cell layers, which enables them to respond to IGF-1 in vitro. Sims et al, using mice with GH receptor KO, showed that IGF-1 administration stimulates the growth (width) of the tibial growth plate and that IGF-1 has a GH independent effect on the growth plate. These findings are similar to those found when treating hypophysectomised rats with IGF-1. In conclusion, IGF-1 is an important growth hormone, mediating the anabolic and linear growth promoting effect of pituitary GH protein. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH."
    }
]